Preclinical pharmacology of zoledronic acid

Seminars in Oncology

Volumn 29, Issue 6 SUPPL. 21, 2002, Pages 3-11

  Green, Jonathan R ^a  

^a NOVARTIS PHARMA AG   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

ALENDRONIC ACID; AMINO TERMINAL TELOPEPTIDE; CALCITRIOL; CLODRONIC ACID; DEOXYPYRIDINOLINE; ETIDRONIC ACID; GERANYLTRANSFERASE; HYDROXYPROLINE; IBANDRONIC ACID; NERIDRONIC ACID; OLPADRONIC ACID; OSTEOCLAST DIFFERENTIATION FACTOR; OSTEOPROTEGERIN; PAMIDRONIC ACID; PEPTIDE DERIVATIVE; PYRIDINOLINE; RISEDRONIC ACID; UNCLASSIFIED DRUG; ZOLEDRONIC ACID;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; BONE MASS; BONE METABOLISM; BONE METASTASIS; BONE MINERALIZATION; CALCIUM BLOOD LEVEL; CLINICAL TRIAL; CONFERENCE PAPER; DOSE RESPONSE; DRUG EFFECT; DRUG MECHANISM; DRUG POTENCY; ENZYME ACTIVITY; HUMAN; IC 50; IN VITRO STUDY; MULTIPLE MYELOMA; NONHUMAN; OSTEOLYSIS; OVARIECTOMY; PRENYLATION; PRIORITY JOURNAL; TUMOR GROWTH;

ANIMALS; BONE DENSITY; BONE NEOPLASMS; BONE REMODELING; BONE RESORPTION; DIPHOSPHONATES; DRUG EVALUATION, PRECLINICAL; HUMANS; IMIDAZOLES;

EID: 0037279873     PISSN: 00937754     EISSN: None     Source Type: Journal    
DOI: 10.1053/sonc.2002.37421     Document Type: Conference Paper

References (51)

1. Fleisch H: Development of bisphosphonates. Breast Cancer Res 4:30-34, 2002
2. Stronski SA, Bettschen-Camin L, Wetterwald A, et al: Bisphosphonates inhibit 1,25-dihydroxyvitamin D3-induced increase of osteocalcin in plasma of rats in vivo and in culture medium of rat calvaria in vitro. Calcif Tissue Int 42:248-254, 1988
3. Russell RGG, Croucher PI, Rogers MJ: Bisphosphonates: pharmacology, mechanisms of action and clinical uses. Osteoporos Int 9:S66-S80, 1999 (suppl 2)
4. Flanagan AM, Chambers TJ: Inhibition of bone resorption by bisphosphonates: Interactions between bisphosphonates, osteoclasts, and bone. Calcif Tissue Int 49:407-415, 1991
5. Rogers MJ, Gordon S, Benford HL, et al: Cellular and molecular mechanisms of action of bisphosphonates. Cancer 88:2961-2978, 2000 (suppl)
6. Sato M, Grasser W, Endo N, et al: Bisphosphonate action. Alendronate localization in rat bone and effects on osteoclast ultrastructure. J Clin Invest 88:2095-2105, 1991
7. Boyce BF, Smith L, Fogelman I, et al: Focal osteomalacia due to low-dose diphosphonate therapy in Paget's disease. Lancet 1:821-824, 1984
8. Bounameaux HM, Schifferli J, Montani JP, et al: Renal failure associated with intravenous diphosphonates. Lancet 1:471, 1983
9. Frith JC, Monkkonen J, Blackburn GM, et al: Clodronate and liposome-encapsulated clodronate are metabolized to a toxic ATP analog, adenosine 5′-(beta, gamma-dichloromethylene) triphosphate, by mammalian cells in vitro. J Bone Miner Res 12:1358-1367, 1997
10. Frith JC, Monkkonen J, Auriola S, et al: The molecular mechanism of action of the antiresorptive and antiinflammatory drug clodronate: Evidence for the formation in vivo of a metabolite that inhibits bone resorption and causes osteoclast and macrophage apoptosis. Arthritis Rheum 44:2201-2210, 2001
11. Pelorgeas S, Martin JB, Satre M: Cytotoxicity of dichloromethane diphosphonate and of 1-hydroxyethane-1,1-diphosphonate in the amoebae of the slime mould Dictyostelium discoideum. A 31P NMR study. Biochem Pharmacol 44:2157-2163, 1992
12. Rogers MJ, Russell RG, Blackburn GM, et al: Metabolism of halogenated bisphosphonates by the cellular slime mould Dictyostelium discoideum. Biochem Biophys Res Commun 189:414-423, 1992
13. Rogers MJ, Ji X, Russell RG, et al: Incorporation of bisphosphonates into adenine nucleotides by amoebae of the cellular slime mould Dictyostelmm discoideum. Biochem J 303: 303-311, 1994
14. Rogers MJ, Watts DJ, Russell RG: Overview of bisphosphonates. Cancer 80:1652-1660, 1997 (suppl)
15. Benford HL, McGowan NWA, Helfrich MH, et al: Visualization of bisphosphonate-induced caspase-3 activity in apoptotic osteoctasts in vitro. Bone 28:465-473, 2001
16. Hughes DE, Wright KR, Uy HL, et al: Bisphosphonates promote apoptosis in murine osteoclasts in vitro and in vivo. J Bone Miner Res 10:1478-1487, 1995
17. Selander KS, Monkkonen J, Karhukorpi EK, et al: Characteristics of clodronate-induced apoptosis in osteoclasts and macrophages. Mol Pharmacol 50:1127-1138, 1996
18. Shinoda H, Adamek G, Felix R, et al: Structure-activity relationships of various bisphosphonates. Calcif Tissue Int 35: 87-99, 1983
19. Green JR, Müller K, Jaeggi KA: Preclinical pharmacology of CGP 42,446, a new, potent, heterocyclic bisphosphonate compound. J Bone Miner Res 9:745-751, 1994
20. Pataki A, Müller K, Green JR, et al: Effects of short-term treatment with the bisphosphonates zoledronate and pamidronate on rat bone: A comparative histomorphometric study on the cancellous bone formed before, during, and after treatment. Anat Rec 249:458-468, 1997
21. Bare S, Kimmel D, Binkley N, et al: Zoledronate (CGP 42,446) suppresses turnover without affecting mineralization in cancellous bone of the ovariectomized non-human primate. J Bone Miner Res 12:S473, 1997 (suppl 1) (abstr)
22. Binkley N, Kimmel D, Bruner J, et al: Zoledronate prevents the development of absolute osteopenia following ovariectomy in adult rhesus monkeys. J Bone Miner Res 13: 1775-1782, 1998
23. Glatt M: The bisphosphonate zoledronate prevents vertebral bone loss in mature estrogen-deficient rats as assessed by micro-computed tomography. Eur Cells Materials 1:18-26, 2001
24. Green JR, Hornby SB, Evans GP, et al: Effect of 1-year treatment with zoledronate (CGP 42446) on bone mineral density, bone mechanical properties and biochemical markers in the ovariectomized rat. J Bone Miner Res 11:S339, 1996 (suppl 1) (abstr)
25. Grynpas MD, Kasra M, Binkley N: Effects of 16-month zoledronate treatment on bone mechanical properties in the ovariectomized adult rhesus monkey. Bone 22:47S, 1998 (suppl) (abstr)
26. O'Rourke C, Bare S, Kimmel D, et al: Zoledronate (CGP 42,446) suppresses turnover in cortical bone of the ovariectomized non-human primate. J Bone Miner Res 12: S473, 1997 (abstr) (suppl 1)
27. Croucher P, De Raeve H, Perry M, et al: Zoledronic acid prevents the development of osteolytic bone disease and increases survival in a murine model of multiple myeloma. Bone 30:39S, 2002 (suppl) (abstr)
28. Green J, Gschaidmeier H, Yoneda T, et al: Zoledronic acid potently inhibits tumour-induced osteolysis in two models of breast cancer metastasis to bone. Ann Oncol 11:14, 2000 (suppl 4) (abstr)
29. Peyruchaud O, Winding B, Pécheur I, et al: Early detection of bone metastases in a murine model using fluorescent human breast cancer cells: Application to the use of the bisphosphonate zoledronic acid in the treatment of osteolytic lesions. J Bone Miner Res 16:2027-2034, 2001
30. Yaccoby S, Pearse RN, Johnson CL, et al: Myeloma interacts with the bone marrow microenvironment to induce osteoclastogenesis and is dependent on osteoclast activity. Br J Haematol 116:278-290, 2002
31. Kurth AA, Kim SZ, Sedlmeyer I, et al: Ibandronate treatment decreases the effects of tumor-associated lesions on bone density and strength in the rat. Bone 30:300-306, 2002
32. Dunford JE, Thompson K, Coxon FP, et al: Structure-activity relationships for inhibition of farnesyl diphosphate synthase in vitro and inhibition of bone resorption in vivo by nitrogen-containing bisphosphonates. J Pharmacol Exp Ther 296:235-242, 2001
33. Alakangas A, Selander K, Mulari M, et al: Alendronate disturbs vesicular trafficking in osteoclasts. Calcif Tissue Int 70:40-47, 2002
34. Fisher JE, Rodan GA, Reszka AA: In vivo effects of bisphosphonates on the osteoclast mevalonate pathway. Endocrinology 141:4793-4796, 2000
35. Mathov I, Plotkin LI, Sgarlata CL, et al: Extracellular signal-regulated kinases and calcium channels are involved in the proliferative effect of bisphosphonates on osteoblastic cells in vitro. J Bone Miner Res 16:2050-2056, 2001
36. Reinholz GG, Getz B, Pederson L, et al: Bisphosphonates directly regulate cell proliferation, differentiation, and gene expression in human osteoblasts. Cancer Res 60:6001-6007, 2000
37. Clohisy DR, O'Keefe PF, Ramnaraine ML: Pamidronate decreases tumor-induced osteoclastogenesis in osteopetrotic mice. J Orthop Res 19:554-558, 2001
38. Van Beek ER, Lowik CW, Papapoulos SE: Bisphosphonates suppress bone resorption by a direct effect on early osteoclast precursors without affecting the osteoclastogenic capacity of osteogenic cells: The role of protein geranylgeranylation in the action of nitrogen-containing bisphosphonates on osteoclast precursors. Bone 30:64-70, 2002
39. Viereck V, Emons G, Lauck V, et al: Bisphosphonates pamidronate and zoledronic acid stimulate osteoprotegerin production by primary human osteoblasts. Biochem Biophys Res Commun 291:680-686, 2002
40. Gowen M, Emery JG, Kumar S: Emerging therapies for osteoporosis. Emerging Drugs 5:1-43, 2000
41. Lacey DL, Timms E, Tan HL, et al: Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation. Cell 93:165-176, 1998
42. Yasuda H, Shima N, Nakagawa N, et al: Osteoclast differentiation factor is a ligand for osteoprotegerin/osteoclastogenesis-inhibitory factor and is identical to TRANCE/RANKL. Proc Natl Acad Sci U S A 95:3597-3602, 1998
43. Morony S, Capparelli C, Sarosi I, et al: Osteoprotegerin inhibits osteolysis and decreases skeletal tumor burden in syngeneic and nude mouse models of experimental bone metastasis. Cancer Res 61:4432-4436, 2001
44. Guise TA, Yin JJ, Taylor SD, et al: Evidence for a causal role of parathyroid hormone-related protein in the pathogenesis of human breast cancer-mediated osteolysis. J Clin Invest 98:1544-1549, 1996
45. Berenson JR, Vescio R, Henick K, et al: A phase I, open label, dose ranging trial of intravenous bolus zoledronic acid, a novel bisphosphonate, in cancer patients with metastatic bone disease. Cancer 91:144-154, 2001
46. Berenson JR, Vescio RA, Rosen LS, et al: A phase I dose-ranging trial of monthly infusions of zoledronic acid for the treatment of osteolytic bone metastases. Clin Cancer Res 7:478-485, 2001
47. Berenson JR, Rosen LS, Howell A, et al: Zoledronic acid reduces skeletal-related events in patients with osteolytic metastases: A double-blind, randomized dose-response study (published erratum appears in Cancer 91:1956, 2001) Cancer 91: 1191-1200, 2001
48. Major P, Lortholary A, Hon J, et al: Zoledronic acid is superior to pamidronate in the treatment of hypercalcemia of malignancy: A pooled analysis of two randomized, controlled clinical trials. J Clin Oncol 19:558-567, 2001
49. Rosen LS, Gordon D, Kaminski M, et al: Zoledronic acid versus pamidronate in the treatment of skeletal metastases in patients with breast cancer or osteolytic lesions of multiple myeloma: A phase III, double-blind, comparative trial. Cancer J 7:377-387, 2001
50. Rosen L, Gordon D, Tchekmedyian S, et al: Zoledronic acid (Zol) significantly reduces skeletal-related events (SREs) in patients with bone metastases from solid tumors. Proc Am Soc Clin Oncol 21:295a, 2002 (abstr)
51. Saad F, Gleason DM, Murray R, et al: A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma. J Natl Cancer Inst 94:1458-1468, 2002